Addex Therapeutics

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ad Hoc Announcement Pursuant to Art.   53 LR   Geneva, Switzerland, June 1 5 , 202 3 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”), announced today that it has increased its share capital from CHF 1,153,483.11 to CHF 1,329,483.11 through the issue of 17,600,000 new registered shares at a nominal value of CHF 0.01 each to Addex Pharma S.A, its 100% wholly-owned subsidiary.

Addex Increases Issued Share Capital to Create Treasury Shares

Ad Hoc Announcement Pursuant to Art.   53 LR   Geneva, Switzerland, May 1 8 , 202 2 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (the Company), announced today that it had received written notification from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for the Company's American Depositary Shares (ADSs) had closed below the minimum US$1.00 per ADS requirement for continued listing on Nasdaq under listing rule 5550(a)(2).

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Addex Therapeutics Ltd. (NASDAQ:ADXN ) Q1 2023 Earnings Conference Call May 11, 2023 10:00 AM ET Company Participants Timothy Dyer – Chief Executive Officer Robert Lütjens – Head of Discovery-Biology Conference Call Participants Boobalan Pachaiyappan – H.C.

Addex Therapeutics Ltd. (ADXN) Q1 2023 Earnings Call Transcript

ADX71149 Phase 2 e pilepsy c linical s tudy's i ndependent i nterim r eview c ommittee (“IRC”) r ecommends c ontinuing s tudy  CHF 5.6M ($ 6.1 M) of cash and cash equivalents at March 31, 202 3 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 11 , 202 3 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Addex Reports Q1 2023 Financial Results and Provides Corporate Update

Cohort 1 progressing through P art 2 Cohort 2 recruiting patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study has been recommended to continue by an Independent Interim Review Committee (IRC) following review of unblinded data from Part 1 of patient Cohort 1.

Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study's Independent Interim Review Committee Recommends Continuing Study

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 5, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its Annual General Meeting will take place on Wednesday May 31, 2023, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).

Addex Convenes Annual General Meeting 2023

Geneva, Switzerland, May 4 , 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Q1 2023 financial results on Thursday, May 11, 2023. Tim Dyer, CEO and Robert Lütjens, Head of Discovery – Biology, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.

Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023

Proceeds to advance allosteric modulator therapeutic pipeline

Addex Completes $5.0 Million Equity Financing

Ad Hoc Announcement Pursuant to Art. 53 LR

Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson's Disease

Addex Raises $5.0 Million in Equity Financing

Addex Therapeutics Ltd. (NASDAQ:ADXN ) Q4 2022 Results Conference Call March 30, 2023 10:00 AM ET Company Participants Timothy Dyer - CEO Robert Lutjens - Head, Discovery Biology Conference Call Participants Raghuram Selvaraju - H.C.

Addex Therapeutics Ltd. (ADXN) Q4 2022 Earnings Call Transcript

Addex Reports Full Year 2022 Financial Results and Provides Corporate Update

Geneva, Switzerland, March 2 8 , 20 2 3 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its full-year 2022 financial results on Thursday, March 30, 2023. Tim Dyer, CEO and Robert Lütjens, Head of Discovery – Biology, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.

Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023

Geneva, Switzerland, March 16, 202 3  - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will participate in the following conferences during the first half of 2023:

Addex Announces Upcoming Conferences it will participate for H1 2023

Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1

Addex Provides Corporate Update and Financial Guidance

Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration

Addex Therapeutics Ltd (NASDAQ:ADXN ) Q3 2022 Results Conference Call November 11, 2022 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and CEO Rob Lütjens - Head of Discovery, Biology Mikhail Kalinichev - Head of Translational Science Conference Call Participants Tim Dyer Hello everyone. I'd like to thank you all for joining our Quarter Three 2022 Financial Results Conference Call.

Addex Therapeutics Ltd (ADXN) Q3 2022 Earnings Call Transcript

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of 0% and 87.13%, respectively, for the quarter ended September 2022.

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates

Addex Reports Q3 2022 Financial Results and Provides Corporate Update

Geneva, Switzerland, November 3 , 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its third quarter 2022 financial results on Friday, November 11, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 11:00 EDT / 08:00 PDT) the same day.

Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022

Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will present at both the Sachs Associates 22nd Annual Biotech in Europe forum in Basel, Switzerland and the Baader Investment Conference in Munich, Germany taking place September 21 - 22, 2022 and September 23, 2022, respectively.

Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference

Start Time: 10:00 January 1, 0000 10:41 AM ET Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2022 Earnings Conference Call August 18, 2022, 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and CEO Roger Mills - Chief Medical Officer Robert Lütjens - Head of Discovery, Biology Conference Call Participants Raghuram Selvaraju - HC Wainwright Bob Pooler - valuationLAB AG Operator Good day and thank you for standing by. Welcome to the Addex Therapeutics to Announce Half Year 2022 Financial Results and provide Corporate Update Conference Call.

Addex Therapeutics Ltd (ADXN) CEO Tim Dyer on Q2 2022 Results - Earnings Call Transcript

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -110.71% and 63.53%, respectively, for the quarter ended June 2022.

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Misses Revenue Estimates

Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update

News for Addex Therapeutics Stock (ADXN)